title: The effects of sunitinib on endometriosis.
abstract: The aim of the present study was to evaluate the effect of sunitinib on endometriotic implants and adhesions in a rat endometriosis model. An experimental endometriosis model was created in 21 rats. These rats were randomly divided into three groups: Group 1 (control group, 7 rats) was given no medication; Group 2 (sunitinib group, 7 rats) was given 3 mg/kg per day of oral sunitinib; and Group 3 (danazol group, 7 rats) was given 7.2 mg/kg per day of oral danazol. The volume of endometriotic implants was calculated. The extent and severity of adhesions were evaluated. The groups were compared by the Student's t-test, analysis of variance (ANOVA) and the Mann-Whitney U test. There was no statistically significant difference in the mean volume of endometriotic implants before medication between three groups. The volume of implants and extent, severity, total score of adhesions were significantly decreased after medication in Group 2 and Group 3. We noted that the volume of the endometriotic implants and adhesion formation were decreased both after sunitinib and danazol treatment. As a result, sunitinib seems to be effective for endometriotic peritoneal lesions. The effects of sunitinib in rat models give hope for improving the treatment of human endometriosis and prevention of pain symptoms.
authors.affiliation: Department of Obstetrics and Gynecology-Perinatology, School of Medicine, Celal Bayar University , Manisa.
authors.forename: H G
authors.initials: HG
authors.lastname: Pala
authors.forename: O
authors.initials: O
authors.lastname: Erbas
authors.forename: E E
authors.initials: EE
authors.lastname: Pala
authors.forename: B
authors.initials: B
authors.lastname: Artunc Ulkumen
authors.forename: L
authors.initials: L
authors.lastname: Akman
authors.forename: T
authors.initials: T
authors.lastname: Akman
authors.forename: F
authors.initials: F
authors.lastname: Oltulu
authors.forename: A
authors.initials: A
authors.lastname: Yavasoglu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D003613:Danazol / Q000627:therapeutic use; D004195:Disease Models, Animal; D004715:Endometriosis / Q000150:complications / Q000188:drug therapy*; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D007211:Indoles / Q000627:therapeutic use*; D010532:Peritoneal Diseases / Q000188:drug therapy* / Q000209:etiology; D011758:Pyrroles / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077210:Sunitinib; D000267:Tissue Adhesions / Q000188:drug therapy / Q000209:etiology
chemical_list: D020533:Angiogenesis Inhibitors; D004965:Estrogen Antagonists; D007211:Indoles; D011758:Pyrroles; D003613:Danazol; D000077210:Sunitinib
keywords: Angiogenesis; danazol; endometriosis; sunitinib; tyrosine-kinase receptor; vascular endothelial growth factor